

December 5, 2017



# **Amarantus Subsidiary Elto Pharma Receives Notice of Allowance for European Patent Application Covering Method of Treating Cognitive Impairment Associated with Alzheimer's Disease and Parkinson's disease with Eltoprazine**

**Once Issued, patent extends coverage for Eltoprazine in Europe into  
2029 CEO to present at RedChip's Global Online Growth Conference  
on December 7, 2017**

SAN FRANCISCO, Dec. 05, 2017 (GLOBE NEWSWIRE) -- [Amarantus Bioscience Holdings, Inc.](#) (OTCPK:AMBS), a US-based biotechnology holding company with wholly-owned subsidiaries developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies, today announced that its wholly-owned subsidiary Elto Pharma, Inc. has received an Intent to Grant a Patent notice from the European Patent Office (EPO) for Eltoprazine. The notice refers to the patent application "Treatment for Neurological and Mental Disorders," and covers the method of treating cognitive impairment or dysfunction associated with Parkinson's disease, Alzheimer's disease, Mild Cognitive Impairment, dementia, or certain other neurological disorders with Eltoprazine. Once issued, the patent will extend Elto Pharma's intellectual property exclusivity for Eltoprazine in Europe into 2029. Elto Pharma is currently redesigning its Phase 2b clinical study for Eltoprazine in the treatment of Levodopa-induced dyskinesia (PD-LID), targeted to begin enrollment in 2018. Eltoprazine has received Orphan Drug Designation from the US FDA for Eltoprazine in the treatment of PD-LID.

## *Redchip Global Online Growth Conference*

Amarantus President & CEO Gerald Commissiong is scheduled to present at RedChip's Global Online Growth Conference on December 7th, 2017, at 2:30p.m. Eastern time. The presentation can be viewed at [www.RedChip.com](http://www.RedChip.com). A live Q&A session will follow the investor presentation.

RedChip's Global Online Growth Conference brings together investors and executives of leading microcap companies, representing a broad spectrum of industries and sectors, including oil & gas, technology, mining, healthcare, consumer goods, energy, and more. More than 10,000 investors attend RedChip's microcap conference series each year. No

registration is required to participate in the conference. Start times are subject to change.

Contact Redchip for further information:

Bruce Haase  
RedChip Companies  
Phone: 407-644-4256  
Email [bruce@redchip.com](mailto:bruce@redchip.com)

### **About Amarantus Bioscience Holdings, Inc.**

Amarantus Bioscience Holdings (OTCPK:AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS' wholly-owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimer's aggression and adult ADHD. AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by AMBS' wholly-owned subsidiary Cutanogen Corporation. AMBS' wholly-owned subsidiary MANF Therapeutics, Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics, Inc. is developing MANF-based products as treatments for brain and ophthalmic disorders. MANF was discovered by the Company's Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS' proprietary discovery engine PhenoGuard. AMBS also owns approximately 80 million shares of Avant Diagnostics, Inc. via the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc. that occurred in May 2016.

For further information please visit [www.Amarantus.com](http://www.Amarantus.com), or connect with the Amarantus on [Facebook](#), [LinkedIn](#), [Twitter](#) and [Google+](#).

### **About Elto Pharma, Inc.**

Eltoprazine is a small molecule 5HT1A/1B partial agonist in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), Alzheimer's aggression and adult attention deficit hyperactivity disorder (adult ADHD). Eltoprazine has been evaluated in over 680 human subjects to date, and has a well-established safety profile, with statistically significant efficacy results across multiple central nervous system indications.

Eltoprazine was originally developed by Abbott Pharmaceuticals in aggression-related indications. The eltoprazine program was out-licensed to PsychoGenics, Inc. (PGI). PGI licensed eltoprazine to Amarantus in 2014 after a successful proof-of-concept trial in PD-LID.

### **Forward-Looking Statements**

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

**Amarantus Investor and Media Contact:**

Ascendant Partners, LLC  
Richard Galterio  
+1-732-410-9810  
[rich@ascendantpartnersllc.com](mailto:rich@ascendantpartnersllc.com)

Source: Amarantus Bioscience Holdings, Inc.



Source: Amarantus Bioscience Holdings, Inc.